This week in techniques

Approach	Summary	Licensing status	Publication and contact information
Drug platforms			
Nanoparticle-conjugated T cells for cancer therapy	<p>Studies in cell culture and in mice suggest that conjugating nanoparticles to T cells could improve the efficacy of adoptive T cell cancer therapy. In a mouse model of melanoma, adoptive transfer of T cells conjugated to cytokine-loaded nanoparticles resulted in complete tumor clearance in all mice, whereas control animals died. Controls received no treatment or unconjugated T cells either alone or with systemically delivered cytokines. Next steps could include studying the mechanisms regulating the retention of the nanoparticle on the T cell surface and evaluating the nanoparticle-conjugated cells in additional cancer models.</p> <p>SciBX 3(34); doi:10.1038/scibx.2010.1052 Published online Sept. 2, 2010</p>	Patent and licensing status unavailable	<p>Stephan, M.T. <i>et al. Nat. Med.</i>; published online Aug. 15, 2010; doi:10.1038/nm.2198</p> <p>Contact: Darrell J. Irvine, Massachusetts Institute of Technology, Cambridge, Mass. e-mail: djirvine@mit.edu</p>